Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Why do we need biosimilars?

Paul Cornes • 21 Mar 2017

Paul Cornes, MD, University Hospital Bristol NHS Foundation Trust, Bristol, UK is one of the UK’s leading experts in biosimilars. Biologic treatments are allowing patients to live longer. Nowadays they can live for many years with some cancers, including chronic blood cancers. Understanding the cost of long-term treatment in cancer, helps us to appreciate how biosimilars could be part of the solution for affordable cancer care.

More from Paul Cornes

Can a epoetin biosimilar be used to treat chemotherapy-induced anemia?
4:16
Can a epoetin biosimilar be used to treat chemotherapy-induced anemia?
Paul Cornes • 22 Jun 2017
Are biosimilars as efficacious as their reference drugs?
2:24
Are biosimilars as efficacious as their reference drugs?
Paul Cornes • 22 Jun 2017
Explaining biosimilars to our patients
1:21
Explaining biosimilars to our patients
Paul Cornes • 27 Jun 2017
Can the dream of affordable cancer care come true?
3:56
Can the dream of affordable cancer care come true?
Paul Cornes • 21 Mar 2017

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals